Abstract
We present the rationale for testing ketamine as an add-on therapy for treating benzodiazepine refractory (established) status epilepticus. In animal studies, ketamine terminates benzodiazepine refractory status epilepticus by interfering with the pathophysiological mechanisms and is a neuroprotectant. Ketamine does not suppress respiration when used for sedation and anesthesia. A Series of reports suggest that ketamine can help terminate refractory and super refractory status epilepticus. We propose to use 1 or 3 mg/Kg ketamine intravenously based on animal-to-human conversion and pharmacokinetic studies. This paper was presented at the 8th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures held in September 2022.
Original language | English (US) |
---|---|
Article number | 109066 |
Journal | Epilepsy and Behavior |
Volume | 141 |
DOIs | |
State | Published - Apr 2023 |
Bibliographical note
Publisher Copyright:© 2022 Elsevier Inc.
Keywords
- Established status epilepticus
- NMDA receptor
- Neuroprotection
- Pharmacokinetics
PubMed: MeSH publication types
- Journal Article
- Research Support, N.I.H., Extramural
- Review